{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:44:54Z","timestamp":1790138694101,"version":"4.0.1"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.bcp.2023.115809","type":"journal-article","created":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T13:22:49Z","timestamp":1694956969000},"page":"115809","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5967-2969","authenticated-orcid":false,"given":"Athanasios","family":"Oikonomou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigia","family":"Valsecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Quadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titus","family":"Watrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Scharov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Wey","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Maria","family":"Savino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Silvestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Valsecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Biondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Borkhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanil","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2955-4528","authenticated-orcid":false,"given":"Giovanni","family":"Cazzaniga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Bardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Palmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bcp.2023.115809_b0005","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1053\/beha.2001.0156","article-title":"Acute lymphoblastic leukaemia","volume":"14","author":"Harrison","year":"2001","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"9","key":"10.1016\/j.bcp.2023.115809_b0010","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.3390\/jcm10091926","article-title":"Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia","volume":"10","author":"Inaba","year":"2021","journal-title":"J. Clin. Med."},{"issue":"12","key":"10.1016\/j.bcp.2023.115809_b0015","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children\u2019s Oncology Group study","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bcp.2023.115809_b0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2141.2010.08312.x","article-title":"Application of genomics for risk stratification of childhood acute lymphoblastic leukaemia: from bench to bedside?","volume":"151","author":"Izraeli","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"16","key":"10.1016\/j.bcp.2023.115809_b0025","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcp.2023.115809_b0030","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","article-title":"PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia","volume":"51","author":"Gu","year":"2019","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.bcp.2023.115809_b0035","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2013-06-509463","article-title":"Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group","volume":"123","author":"Buitenkamp","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bcp.2023.115809_b0040","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood-2009-08-235408","article-title":"Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group","volume":"115","author":"Hertzberg","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bcp.2023.115809_b0045","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ng.469","article-title":"Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia","volume":"41","author":"Mullighan","year":"2009","journal-title":"Nat. Genet."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2023.115809_b0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1615\/CritRevOncog.v16.i1-2.30","article-title":"Understanding the biology of CRLF2-overexpressing acute lymphoblastic leukemia","volume":"16","author":"Tasian","year":"2011","journal-title":"Crit. Rev. Oncog."},{"issue":"7","key":"10.1016\/j.bcp.2023.115809_b0055","doi-asserted-by":"crossref","first-page":"e0220026","DOI":"10.1371\/journal.pone.0220026","article-title":"CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition","volume":"14","author":"Meyer","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bcp.2023.115809_b0060","doi-asserted-by":"crossref","first-page":"e892","DOI":"10.1097\/HS9.0000000000000892","article-title":"Definition and prognostic value of Ph-like and IKZF1 plus status in children with Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia","volume":"7","author":"Palmi","year":"2023","journal-title":"Hemasphere."},{"issue":"2","key":"10.1016\/j.bcp.2023.115809_b0065","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study","volume":"10","author":"Den Boer","year":"2009","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2023.115809_b0070","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2023.115809_b0075","first-page":"12","article-title":"PAX5 alterations in B-cell acute lymphoblastic leukemia","volume":"25","author":"Jia","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2023.115809_b0080","doi-asserted-by":"crossref","first-page":"104224","DOI":"10.1016\/j.ebiom.2022.104224","article-title":"PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120","volume":"83","author":"Fazio","year":"2022","journal-title":"EBioMedicine."},{"issue":"14","key":"10.1016\/j.bcp.2023.115809_b0085","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1182\/blood.2020009032","article-title":"Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants","volume":"137","author":"Fazio","year":"2021","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.bcp.2023.115809_b0090","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.19.00261","article-title":"Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study","volume":"37","author":"Pieters","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115809_b0095","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3324\/haematol.2015.131680","article-title":"Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome","volume":"101","author":"Oskarsson","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bcp.2023.115809_b0100","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/pbc.21737","article-title":"Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with Down syndrome","volume":"52","author":"Shah","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2023.115809_b0105","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.3324\/haematol.2019.224774","article-title":"Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen","volume":"105","author":"Kroll","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bcp.2023.115809_b0110","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41375-021-01341-y","article-title":"Identification and characterization of relapse-initiating cells in MLL-rearranged infant ALL by single-cell transcriptomics","volume":"36","author":"Candelli","year":"2022","journal-title":"Leukemia [Internet]."},{"issue":"7","key":"10.1016\/j.bcp.2023.115809_b0115","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1172\/JCI134424","article-title":"Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL","volume":"130","author":"Hurtz","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2023.115809_b0120","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2017.07.013","article-title":"Drug repurposing in cancer","volume":"124","author":"Sleire","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2023.115809_b0125","doi-asserted-by":"crossref","first-page":"106781","DOI":"10.1016\/j.compbiomed.2023.106781","article-title":"A drug repurposing approach for individualized cancer therapy based on transcriptome sequencing and virtual drug screening","volume":"157","author":"Kadioglu","year":"2023","journal-title":"Comput. Biol. Med."},{"issue":"3","key":"10.1016\/j.bcp.2023.115809_b0130","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/blood-2017-10-810986","article-title":"Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response","volume":"132","author":"Bhatia","year":"2018","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bcp.2023.115809_b0135","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","article-title":"Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia","volume":"3","author":"Pemovska","year":"2013","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.bcp.2023.115809_b0140","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.3390\/ijms24044235","article-title":"Hydrogel-Based Pre-Clinical Evaluation of Repurposed FDA-Approved Drugs for AML","volume":"24","author":"James","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.bcp.2023.115809_b0145","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/bjh.18735","article-title":"Abemaciclib drives the therapeutic differentiation of acute myeloid leukaemia stem cells","volume":"201","author":"Xie","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcp.2023.115809_b0150","doi-asserted-by":"crossref","first-page":"1117988","DOI":"10.3389\/fped.2023.1117988","article-title":"Feasibility of high-throughput drug sensitivity screening (HDS)-guided treatment for children with refractory or relapsed acute myeloid leukemia","volume":"11","author":"Lv","year":"2023","journal-title":"Front. Pediatr."},{"issue":"6","key":"10.1016\/j.bcp.2023.115809_b0155","doi-asserted-by":"crossref","first-page":"2202506","DOI":"10.1002\/adhm.202202506","article-title":"Microphysiological Drug-Testing Platform for Identifying Responses to Prodrug Treatment in Primary Leukemia","volume":"12","author":"G\u00f6k\u00e7e","year":"2023","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.bcp.2023.115809_b0160","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10030638","article-title":"High-Throughput Drug Library Screening in Primary KMT2A-Rearranged Infant ALL Cells Favors the Identification of Drug Candidates That Activate P53 Signaling","volume":"10","author":"Wander","year":"2022","journal-title":"Biomedicines."},{"key":"10.1016\/j.bcp.2023.115809_b0165","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9070711","article-title":"Irinotecan Induces Disease Remission in Xenograft Mouse Models of Pediatric MLL-Rearranged Acute Lymphoblastic Leukemia","volume":"9","author":"Kerstjens","year":"2021","journal-title":"Biomedicines."},{"issue":"1","key":"10.1016\/j.bcp.2023.115809_b0170","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/s41467-022-29224-5","article-title":"Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines","volume":"13","author":"Leo","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2023.115809_b0175","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41591-022-02112-7","article-title":"Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response","volume":"29","author":"Lee","year":"2023","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.bcp.2023.115809_b0180","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-022-00683-9","article-title":"Potential role of STAG1 mutations in genetic predisposition to childhood hematological malignancies","volume":"12","author":"Saitta","year":"2022","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.bcp.2023.115809_b0185","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1158\/2643-3230.BCD-19-0059","article-title":"An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities","volume":"2","author":"Fl\u00fcmann","year":"2021","journal-title":"Blood Cancer Discov."},{"issue":"1","key":"10.1016\/j.bcp.2023.115809_b0190","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/srep05193","article-title":"Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies","volume":"4","author":"Yadav","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2023.115809_b0195","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.976065","article-title":"Patient-derived cancer models: Valuable platforms for anticancer drug testing","volume":"12","author":"Genta","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115809_b0200","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12967-022-03405-8","article-title":"Patient-derived xenograft (PDX) models, applications and challenges in cancer research","volume":"20","author":"Abdolahi","year":"2022","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.bcp.2023.115809_b0205","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","article-title":"Patient-derived xenograft models in cancer therapy: technologies and applications","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"11","key":"10.1016\/j.bcp.2023.115809_b0210","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","article-title":"Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia","volume":"129","author":"Frismantas","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bcp.2023.115809_b0215","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809443","article-title":"PDX models recapitulate the genetic and epigenetic landscape of pediatric T-cell leukemia","volume":"10","author":"Richter-Pecha\u0144ska","year":"2018","journal-title":"EMBO Mol. Med."},{"issue":"11","key":"10.1016\/j.bcp.2023.115809_b0220","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3954","article-title":"High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response","volume":"21","author":"Gao","year":"2015","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.bcp.2023.115809_b0225","doi-asserted-by":"crossref","first-page":"e14608","DOI":"10.15252\/emmm.202114608","article-title":"In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer","volume":"14","author":"Lau","year":"2022","journal-title":"EMBO Mol. Med."},{"issue":"10","key":"10.1016\/j.bcp.2023.115809_b0230","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1093\/annonc\/mdx416","article-title":"Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors","volume":"28","author":"Izumchenko","year":"2017","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2023.115809_b0235","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/1535-7163.MCT-10-0106","article-title":"Analysis of Food and Drug Administration-Approved Anticancer Agents in the NCI60 Panel of Human Tumor Cell Lines","volume":"9","author":"Holbeck","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.bcp.2023.115809_b0240","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3324\/haematol.2019.217414","article-title":"Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types","volume":"105","author":"Majumder","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.bcp.2023.115809_b0245","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/978-1-4939-2895-8_14","article-title":"Glucocorticoids and Cancer","volume":"872","author":"Pufall","year":"2015","journal-title":"Adv. Exp. Med. Biol."},{"issue":"2","key":"10.1016\/j.bcp.2023.115809_b0250","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1042\/BCJ20160583","article-title":"Topoisomerases as anticancer targets","volume":"475","author":"Delgado","year":"2018","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcp.2023.115809_b0255","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910317","article-title":"Role of HSP90 in Cancer","volume":"22","author":"Birbo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2023.115809_b0260","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1158\/2159-8290.CD-17-0605","article-title":"BET Proteins as Targets for Anticancer Treatment","volume":"8","author":"Stathis","year":"2018","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.bcp.2023.115809_b0265","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/leu.2013.226","article-title":"Targeting the PI3K\/Akt\/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential","volume":"28","author":"Neri","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2023.115809_b0270","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3389\/fonc.2014.00263","article-title":"The Biology and Targeting of FLT3 in Pediatric Leukemia","volume":"4","author":"Annesley","year":"2014","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115809_b0275","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/sj.leu.2403231","article-title":"Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation","volume":"18","author":"Menendez","year":"2004","journal-title":"Leukemia"},{"issue":"52","key":"10.1016\/j.bcp.2023.115809_b0280","doi-asserted-by":"crossref","first-page":"89923","DOI":"10.18632\/oncotarget.21027","article-title":"JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia","volume":"8","author":"Steeghs","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.bcp.2023.115809_b0285","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of Acute Lymphoblastic Leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bcp.2023.115809_b0290","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","article-title":"Venetoclax: First Global Approval","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2023.115809_b0295","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212574","article-title":"Venetoclax: evidence to date and clinical potential","volume":"8","author":"Ju\u00e1rez-Salcedo","year":"2019","journal-title":"Drugs Context."},{"issue":"1","key":"10.1016\/j.bcp.2023.115809_b0300","first-page":"103","article-title":"Taxol (paclitaxel) was approved by FDA for the treatment of patients with recurrent ovarian cancer","volume":"54","author":"Menzin","year":"1994","journal-title":"Gynecol. Oncol."},{"issue":"25","key":"10.1016\/j.bcp.2023.115809_b0305","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","article-title":"ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia","volume":"124","author":"Peirs","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bcp.2023.115809_b0310","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.bcp.2023.115809_b0315","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","article-title":"Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia","volume":"20","author":"Richard-Carpentier","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"8","key":"10.1016\/j.bcp.2023.115809_b0320","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1158\/1535-7163.MCT-17-1123","article-title":"Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4(+) Infant ALL","volume":"17","author":"Bardini","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.bcp.2023.115809_b0325","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/cancers15030984","article-title":"Heat-Shock Proteins in Leukemia and Lymphoma: Multitargets for Innovative Therapeutic Approaches","volume":"15","author":"Cabaud-Gibouin","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.bcp.2023.115809_b0330","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-021-00450-2","article-title":"HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias","volume":"11","author":"Mshaik","year":"2021","journal-title":"Blood Cancer J."},{"issue":"22","key":"10.1016\/j.bcp.2023.115809_b0335","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1182\/blood-2015-03-635821","article-title":"Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias","volume":"126","author":"Kucine","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bcp.2023.115809_b0340","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood-2016-03-707414","article-title":"Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia","volume":"128","author":"Khaw","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bcp.2023.115809_b0345","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1182\/bloodadvances.2019001416","article-title":"Cotargeting BCL-2 and MCL-1 in high-risk B-ALL","volume":"4","author":"Moujalled","year":"2020","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.bcp.2023.115809_b0350","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/s41375-021-01502-z","article-title":"Synergistic activity of combined inhibition of anti-apoptotic molecules in B-cell precursor ALL","volume":"36","author":"Seyfried","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.bcp.2023.115809_b0355","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1158\/0008-5472.CAN-18-0236","article-title":"Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia","volume":"79","author":"Diaz-Flores","year":"2019","journal-title":"Cancer Res."},{"issue":"354","key":"10.1016\/j.bcp.2023.115809_b0360","doi-asserted-by":"crossref","first-page":"354ra114","DOI":"10.1126\/scitranslmed.aaf5309","article-title":"Targeting BCL-2 and ABL\/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"8","author":"Leonard","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.bcp.2023.115809_b0365","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/ng.3362","article-title":"Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options","volume":"47","author":"Fischer","year":"2015","journal-title":"Nat. Genet."},{"issue":"12","key":"10.1016\/j.bcp.2023.115809_b0370","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.celrep.2015.12.003","article-title":"MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199","volume":"13","author":"Benito","year":"2015","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.bcp.2023.115809_b0375","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41375-022-01746-3","article-title":"Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy","volume":"37","author":"Cheung","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bcp.2023.115809_b0380","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3390\/cancers14010150","article-title":"Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma","volume":"14","author":"Gibson","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223004008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223004008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T14:34:55Z","timestamp":1736346895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295223004008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":76,"alternative-id":["S0006295223004008"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115809","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115809","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115809"}}